This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis To Present At Upcoming Health Care And Investor Conferences

LEXINGTON, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will present at the following upcoming conferences:
  • Stifel Nicolaus 2012 Healthcare Conference – Thursday, September 6, at 1:30 p.m. EDT in Boston. A corresponding webcast of this presentation can be accessed by visiting:

http://www.veracast.com/webcasts/stifel/healthcare2012/93210361.cfm
  • BioCentury NewsMakers in the Biotech Industry Conference – Friday, September 7, at 3:00 p.m. EDT in New York City. A corresponding webcast of this presentation can be accessed by visiting:

http://www.media-server.com/m/p/yft3bh5e

Dan Passeri, President and Chief Executive Officer, will provide an overview of Curis' development programs, including Erivedge™ (vismodegib), CUDC-101, CUDC-907 and Debio 0932, as well as discuss other corporate activities. 

The presentations will be archived shortly after the live events and available for 30 days following the conferences. In addition, presentations will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com .

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com .

The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347
CONTACT: Michael P. Gray
         CFO & COO
         Curis, Inc.
         617-503-6632
         mgray@curis.com

Curis, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs